Aug 18
CSLLY · Csl Ltd
Market Cap
$66.05B
Shares
1.92B
Volume · Nov 13
37.78K
Avg daily vol (3M)
84.76K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$34.41
Open$34.60
Day$34.32–34.60
52W close$16.35–35.39
Avg vol 30d49K
Short int160K · 0.0% of shares · 2.1d
Short vol43%
Last earningsAug 18, 2026
DataJan 2020–Nov 2026
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
2.1%
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.0%
Latest settlement · 2.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
High
Market backdrop
VIX 19.3 · elevated
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+33%
above
Price vs 50-day avg
+5%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
+98%
trailing
YTD return
+19%
this year
Relative strength
+97%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $33 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
7 of 6 funds reported for Sep 30 · net +1.8K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of shares out · ▼ -12.2% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Squeeze score
37
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
40%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
2.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 18, 2026
FY27
Transformation program savings
$220M
Incremental savings
$220M
Annualised savings
$400M
NPAT excluding restructuring impairment items
Non-GAAP
5%
fiscal year 27 versus fiscal year 26
Cost out of the business
$220M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+33%
Bullish
Price vs 50-day avg
+5%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $33 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
7 of 6 funds reported for Sep 30 · net +1.8K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.01% of shares out · ▼ -12.2% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
6 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $16
Now $34 · 95%
Range high $35
vs 200-day avg +33%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CSLLY
this stock
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
ARGX
Argenx SE
|
$60.37B | +14.2% | — | — | 2.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CSLLY | -1.0% | +3.2% | +97.7% | -2.8% | +19.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -3.6% | +4.3% | +97.2% | -2.6% | +8.9% |
Capital returns
Latest dividend
$0.405
/ share · ex Sep 10, 2026
Paid (TTM)
$0.73
/ share · 2 payouts
Dividend yield (TTM, derived)
— · history filling in
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.